[ad_1]
Lyon, France, March 6, 2024–(Business Wire)–Supervision News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that its management team plans to participate in the following upcoming conferences:
-
36th Annual Ross Conference – March 17-19, Dana Point, California, USA
The event provides investors with the opportunity to hear and meet with executive management from approximately 500 private and public companies.
-
BioEuropean Spring – March 18-20, Barcelona, Spain
It’s the premier spring collaboration event, bringing together more than 2,000 companies for one-on-one meetings.
-
French Diabetes Association Congress – March 19-22, Toulouse, France
This congress covers all aspects of modern diabetology, from basic knowledge to clinical practice, with a special focus on therapeutic and technological innovations and e-health.
-
Investors enter – April 4-5, Paris, France
Aimed specifically at individual shareholders, the event brings companies and investors together for two days of conferences and pre-hosted sessions.
-
Cells and Genes in Medicine Conference – April 9-11, Rome, Italy
This is the leading conference bringing together the fields of cell and gene therapy. The program covers a wide range of topics (from market access to regulation, manufacturing or financing) and features expert-led panels, one-on-one collaboration capabilities and presentations from leading companies.
-
LSX World Congress – April 29-30, London, UK
The event brings together CEOs and senior decision-makers from the world’s most innovative biopharmaceutical, medtech and healthtech companies as well as investors, senior BD&L teams, R&D leaders and industry KOLs.
-
Spring Stock Forum – May 13-15, Frankfurt, Germany
Around 120 listed companies from Germany and abroad take part in the event to present their latest business data and prospects for the next fiscal year to selected investors, analysts, financial journalists and other capital market participants.
About Adosia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the area of metabolic diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® Technology to develop a new generation of insulin and products combining insulin with other classes of hormones; 2) Oral administration®an oral peptide delivery technology; 3) AdoShell®an immunoprotective biomaterial for cell transplantation, initially applied to pancreatic cell transplantation; and 4) Adogel®a long-acting drug delivery platform.
Adocia holds over 25 patent families. The company is headquartered in Lyon and has approximately 80 employees. Adocia listed on Euronext regulated marketTM value Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements regarding Adocia and its business. Such forward-looking statements are based on assumptions that Adocia believes are reasonable.However, there can be no assurance that the estimates contained in such forward-looking statements will be achieved as such estimates are subject to various risks, including those listed in the “Risk Factors” section of the universal registration document filed on April 26, 2023. Signed with the French Financial Market Authority and updated in accordance with the amendments of July 26, 2023 (D.23-0346-A01) and September 13, 2023 (D.23-0346-A02), available Obtained at www.adocia.com, especially the uncertainties inherent in research and development, future clinical data, analytics and the evolution of the economic environment, financial markets and markets in which Adocia operates, which may impact the company’s short-term financing needs and its ability to raise additional capital.
The forward-looking statements contained in this press release are subject to risks that Adocia is not aware of or that, as of this date, Adocia does not consider to be material. The occurrence of all or part of these risks could cause Adocia’s actual results, financial condition, performance or achievements to be materially different from those reflected in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306184245/en/
contact method
Adosia
Olivier Sulla
CEO
Contact investisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Ulithi Communications
Adocia News and Investor Relations
Pierre Louis Germain
Bruno Arabian
adocia@ulysse-communication.com
+ 33 (0)6 64 79 97 51
[ad_2]
Source link